TYRA (Tyra Biosciences) ROE % Adjusted to Book Value: -8.27% (As of Mar. 2026)


TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $31.88
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences ROE % Adjusted to Book Value?

Tyra Biosciences TYRA +3.07% 28 ROE % Adjusted to Book Value is -8.27% as of Mar. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Tyra Biosciences's ROE % for the quarter that ended in Mar. 2026 was -48.62%. Tyra Biosciences's PB Ratio for the quarter that ended in Mar. 2026 was 5.88. Tyra Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -8.27%.

Tyra Biosciences ROE % Adjusted to Book Value Related Terms

Tyra Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences ROE % Adjusted to Book Value Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -9.46 -15.82 -10.25 -15.34 -7.31

Tyra Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.08 -21.26 -15.42 -9.20 -8.27

TYRA vs ZLAB, OCUL, AUPH: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Tyra Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's ROE % Adjusted to Book Value falls into.


TYRA
28GF Score
Tyra Biosciences Inc TYRA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences ROE % Adjusted to Book Value Calculation

Tyra Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-39.83% / 5.45
=-7.31%

Tyra Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-48.62% / 5.88
=-8.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -8.27% mean?
Tyra Biosciences (TYRA) has a ROE % Adjusted to Book Value of -8.27% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tyra Biosciences and its competitors.
Is Tyra Biosciences' ROE % Adjusted to Book Value too high?
Tyra Biosciences' current ROE % Adjusted to Book Value is -8.27%. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' ROE % Adjusted to Book Value compare to ZLAB and OCUL?
Tyra Biosciences' ROE % Adjusted to Book Value of -8.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current ROE % Adjusted to Book Value is -8.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current ROE % Adjusted to Book Value of -8.27%. The current ROE % Adjusted to Book Value is -8.27%. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current ROE % Adjusted to Book Value is -8.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.88
Price